Since all four incident cases were nurses and 2 of 21 reporting
needle-stick accidents developed HCV viremia, the most costeffective
approach for preventive HCV vaccine trials would be to
enroll only the hospital personnel directly involved in patient care
who are reporting needle-stick injuries. This approach focuses upon
those at greatest risk of exposure to HCV. Increasing the number of
eligible candidates would require recruiting subjects from multiple
units and numerous hospitals that care for patients with chronic
liver disease in Egypt, where chronic HCV is by far the most common
cause of chronic liver disease